期刊文献+

PTD-Foxp3融合蛋白的表达、纯化及其生物学功能初步研究 被引量:6

Expression,purification of PTD-Foxp3 fusion protein and analyse its bioactivity
下载PDF
导出
摘要 目的:构建带HIV-1 TAT转录因子的穿膜序列(Protein transduction domain,PTD)的pET28a-PTD-Foxp3原核表达载体,表达纯化PTD-Foxp3融合蛋白,并研究其生物学作用。方法:利用基因重组技术构建pET28a-PTD-Foxp3融合蛋白表达载体,并在大肠埃希菌Rosetta(DE3)中表达融合蛋白,经Ni2+分离柱纯化pET28a-PTD-Foxp3融合蛋白。流式细胞术检测融合蛋白穿越细胞膜进入小鼠T淋巴细胞瘤株EL-4细胞中的能力,并通过混合淋巴细胞反应初步分析融合蛋白抑制T细胞活化增殖的生物学作用。结果:成功地构建了pET28a-PTD-Foxp3融合蛋白表达载体,表达并纯化了pET28a-PTD-Foxp3融合蛋白。通过流式细胞术分析证实pET28a-PTD-Foxp3融合蛋白能有效地进入细胞内;同时经混合淋巴细胞反应证明该融合蛋白能明显抑制T细胞的活化增殖能力。结论:成功表达具有生物学活性的PTD-Foxp3融合蛋白,为进一步研究PTD-Foxp3融合蛋白免疫抑制功能和构建表达人PTD-Foxp3融合蛋白,最终应用于临床疾病的治疗奠定了基础。 Objective: To express and purify mouse PTD-Foxp3 fusion protein and investigate its biofunction in T ceils. Methods: Expression vector of PTD-Foxp3 was constructed with inserting the PCR products of PTD-Foxp3 into pET28a Vector. The fusion protein was expressed by E. coli Rosetta ( DE3 ) and purified by Bio-Rad Profinity IMAC Ni-Charged Resin. A flow cytometry assay was used to detect the effect of PTD-Foxp3 to transduce into the cell cytoplasm. The capability of PTD-Foxp3 for inhibiting the proliferation of T ceils was analyzed by mixed lympocyte reaction (MLR). Results: A prokaryotic expression vector of pET28a-PTD-Foxp3 was successfully constructed and the fusion protein was expressed and purified efficiently. The results of flow cytometry indicated that pET28a-PTD-Foxp3 fusion protein could transduce into EL-4 efficiently. MLR confirmed that the fusion protein could inhibit the proliferation of T cells. Conclusion: The present study describes PTD-Foxp3 fusion proteins as a powerful anti-T cell proliferation tools. This study suggested that the PTD-Foxp3 fusion protein may be use for clinical autoimmune disease and transplantation rejection therapy.
出处 《江苏大学学报(医学版)》 CAS 2007年第3期188-192,196,共6页 Journal of Jiangsu University:Medicine Edition
基金 国家自然科学基金资助项目(30671984 30471627 30300169) 江苏省自然科学基金资助项目(BK2004405)
关键词 PTD Foxp3融合蛋白 免疫抑制 protein transduction domain PTD-Foxp3 fusion protein immune inhibition
  • 相关文献

参考文献9

  • 1Gavin MA,Torqerson TR,Rudensky AY,et al.Single-cell analysis of normal and FOXP3-mutant human T cells:FOXP3 expression without regulatory T cell development[J].Proc Natl Acad Sci USA,2006,103(17):6659-6664. 被引量:1
  • 2Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J] Science,2003,299(5609):1057-1061. 被引量:1
  • 3Liu Y,Li JL,Johnny JH.HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa,tip110[J].J Biol Chem,2002,277(26):23854-23863. 被引量:1
  • 4Kathrin R,Loddenkemper C,Maul J,et al.Mucosal FOXP3^+ regulatory T cells are numericallydeficient in acute and chronic GvHD[J].Blood,2006,107(4):1717-1723. 被引量:1
  • 5Sullivan KE,McDonald-McGinn D,Zackai E.CD4^+ CD25^+ T-cell productionin healthy humans and in patients with thymic hypoplasia[J].Clin Diag Lab Immunol,2002,9(5):1129-1131. 被引量:1
  • 6Ochs HD,Ziegler SF,Torgerson TR.FOXP3 acts as a rheostat of the immune response[J].Immunol Rev,2005,203(2):156-164. 被引量:1
  • 7Severine LB,Raif SG.IPEX and the role of Foxp3 in the development and function of human Tregs[J].J Biol Chem,2006,116(6):1473-1475. 被引量:1
  • 8Loser K,Hansen W,Beissert S,et al.In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic auroimmunity[J].Gene Ther,2005,12(17):1294-1304. 被引量:1
  • 9Jaeckel E,Boehmer HV,Manns PM.Antigen-specific Foxp3-transduced T-cells can controlestablished type 1 diabetes[J].Diabetes,2005,54(2):306-310. 被引量:1

同被引文献90

  • 1王莉,孟刚,牛微,杨空明,徐文岳,赵婷婷,唐艳,赵建平,吴玉章.CPP Tat_(49-57)促进外源CTL表位进入MHC-Ⅰ类抗原呈递途径的机制研究[J].免疫学杂志,2006,22(3):247-251. 被引量:4
  • 2刘秋英,王一飞,熊盛,张美英,钱垂文,何旭君.TAT-NDPK-A蛋白的构建表达及穿膜初步研究[J].中国药学杂志,2007,42(9):652-655. 被引量:2
  • 3Vives E. Present and future of cell-penetrating peptide mediated delivery systems:"is the trojan horse too wild to go only to troy? " [J]. J Control Release, 2005, 109(1-3): 77-85. 被引量:1
  • 4Hansen M, Kilk K, Langel U, et al. Predicting cell-penetrating peptides [J]. Adv Drug Deliv Rev, 2008, 60(4-5) : 572-579. 被引量:1
  • 5Green M, Loewenstein P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT transactivator protein [J]. Cell, 1988, 55(6): 1179-1188. 被引量:1
  • 6Green M, Ishino M, Loewenstein P M. Mutational analysis of HIV-1 TAT minimal domain peptides: identification of trans-domaint mutants that suppress HIV-LTR-driven gene expression[J]. Cell, 1989, 58 ( 1 ) :215-223. 被引量:1
  • 7Juliano R. Review of cell penetrating peptides: processes and applications[J]. J Control Release, 2003, 93(1): 88-89. 被引量:1
  • 8Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery [J]. Adv Drug Deliv Rev, 2005, 57(4) : 529-545. 被引量:1
  • 9Elmquist A, Hansen M, Langel U, Structure-activity relationship study of the cell-penetrating peptide pVEC [ J ]. Biochim Biophys Acta, 2006, 1758(6): 721-729. 被引量:1
  • 10Geisler I, Chmielewski J. Probing length effects and mechanism of cell penetrating agents mounted on a polyproline helix scaffold. [ J]. Bioorg Med Chem Lett, 2007, 17(10) : 2765- 2768. 被引量:1

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部